JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krieter, P. A.
Right arrow Articles by Stearns, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krieter, P. A.
Right arrow Articles by Stearns, R. A.

Absorption and glucuronidation of the angiotensin II receptor antagonist losartan by the rat intestine

PA Krieter, AE Colletti, RR Miller and RA Stearns

Department of Drug Metabolism, Merck Research Laboratories, Rahway, New Jersey 07065, USA.

The absorption and metabolism by the rat intestine of the tetrazole- containing angiotensin II receptor antagonist losartan were determined using in vitro, in situ and in vivo models of absorption. The permeability coefficient of losartan was similar at mucosal concentrations of 0.5 to 2 mM when assayed using segments of jejunum in the Sweetana/Grass diffusion cell. The compound was conjugated during transport to form a glucuronide at the N2-position of the tetrazole group; the structure was confirmed by LC/MS/MS. Approximately 12% to 20% of losartan transported across the duodenum and jejunum was conjugated to the glucuronide. The glucuronide was not detected when sections of the ileum or colon were used. In the in situ intestinal loop model, 18% to 23% of the losartan injected into the lumen was recovered in the mesenteric vein by 1 hr. As in the in vitro model, 11% to 15% of the compound was conjugated on the tetrazole group during absorption. EXP-3174, the pharmacologically active carboxylic acid metabolite of losartan, was not detected in either the serosal buffer from the in vitro study or the mesenteric plasma from the in situ intestinal loop. In conscious rats, N2-glucuronide was detected in plasma samples from the portal vein soon after oral administration of losartan. It was detected at low concentrations in only a few of the arterial samples assayed. In conclusion, losartan is conjugated with glucuronic acid at the N2-position of the tetrazole group during absorption by the rat upper gastrointestinal tract.

Volume 273, Issue 2, pp. 816-822, 05/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
J. C. Stevens, J. L. Fayer, and K. C. Cassidy

Drug Metab. Dispos., March 1, 2001; 29(3): 289 - 295.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1995 by the American Society for Pharmacology and Experimental Therapeutics.